Exact Sciences CCO Everett Cunningham departs; reaffirms Q2 and FY 2024 guidance

EXACT SCIENCES CORP

Chief Commercial Officer Everett Cunningham departing June 13, 2024 for a non-competing opportunity.
Commercial organization reorganized under Screening and Precision Oncology teams; GMs Orville and Baranick continue.
Reaffirmed Q2 2024 total revenue guidance of $677-697M; Screening $522-532M, Precision Oncology $155-165M.
Reaffirmed full-year 2024 total revenue $2.810-2.850B and adjusted EBITDA $325-350M.

item 5.02 item 7.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Everett Cunningham

Chief Commercial Officer

EXACT SCIENCES CORP

Effective: 2024-06-13
Filed: June 3, 2024, 7:59 PM ET

Exact Sciences also reported that on May 30, 2024, Everett Cunningham, Chief Commercial Officer, informed the Company that effective on June 13, 2024 he will be departing for an opportunity with an organization that does not compete with the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Everett Cunningham departed as Chief Commercial Officer at EXACT SCIENCES CORP.

Action: departing
Role: Chief Commercial Officer

Exact text from the filing

Exact Sciences also reported that on May 30, 2024, Everett Cunningham, Chief Commercial Officer, informed the Company that effective on June 13, 2024 he will be departing for an opportunity with an organization that does not compete with the Company.

View on SEC.gov

Source: SEC EDGAR

accession 0001124140-24-000051

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.